Here is what the page “Weight-Loss Drugs Like Ozempic May Slow Biological Aging, Eli Lilly Suggests” contains. Eli Lilly, the maker of weight-loss drugs such as Mounjaro and Zepbound, is exploring whether these medications can do more than help people shed pounds. The company suggests that popular GLP-1 receptor agonists might also slow biological aging, potentially extending healthspan. This comes as researchers investigate the broader effects of these drugs beyond diabetes and obesity, including their impact on heart health, inflammation, and cellular aging processes.
If confirmed, such benefits could transform how we approach age-related diseases and longevity. Meanwhile, the tech world is also buzzing about carbon dioxide batteries—a novel energy storage solution that uses CO2 to store renewable power, offering a potential alternative to lithium-ion batteries. These developments highlight a growing intersection of biotechnology and clean energy in addressing global challenges. The full version stays on the original page, which this listing opens directly.